Drug offers new pain management therapy for diabetics
A study shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain.
A study from the University of Calgary's Hotchkiss Brain Institute shows there is evidence to support a new drug therapy called nabilone to treat diabetic neuropathy, or nerve pain. Researchers enrolled 60 patients with diabetic neuropathy in a 12-week placebo controlled clinical study. At the end of the study, patients reported less pain and an improvement in sleep and anxiety when taking nabilone as compared to the placebo.
"This is a good option to help treat nerve pain due to diabetes, with very few side effects," says Dr. Cory Toth, a neurologist and the study's lead researcher. Toth is a member of the University of Calgary's Hotchkiss Brain Institute, Department of Clinical Neurosciences and is the research director of the Calgary Chronic Pain Centre Clinic.
The medication used in the study has the generic name nabilone, and is currently used in Canada to treat nausea in chemotherapy patients. This study gives doctors more evidence to support its prescription for treating neuropathy pain in diabetics. Nabilone is a synthetic cannabinoid, which mimics some of the chemical compounds of cannabis, or marijuana. It is approved for use by Health Canada and the FDA.
"This study is a further demonstration of the potential medical benefits of cannabinoids in a difficult pain condition. Dr. Toth and his team have conducted a solid trial which, although small, validates our clinical experience. This study gives physicians support to consider further options in treating this devastating chronic pain disorder," says Dr. Mark Ware, Associate Professor at the McGill University Health Centre.
Type 2 diabetes is exploding at epidemic rates over the world, and Canada is no exception. Recent studies show that type 2 diabetes is present in close to 10 per cent of Canadian adults and growing at faster than predicted rates.
Diabetic neuropathy is damage caused to the nerves, which results in numbness, tingling, burning and pain. About half of all diabetics suffer from diabetic neuropathy, and about half of this group experiences extreme pain, sleep disturbances, and difficulties walking.
Leslie Bonenfant knows firsthand the pain associated with diabetic neuropathy. She was diagnosed with type 2 diabetes five years ago. Having participated in the study, she experienced positive results, "My pain was so severe that I could barely walk a block. After taking nabilone I can manage my pain and I can function day to day," say says.
The study was published in the October issue of the medical journal Pain. It was funded by a grant from Valeant Canada.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance